Stay updated on Depemokimab in Severe Asthma Clinical Trial
Sign up to get notified when there's something new on the Depemokimab in Severe Asthma Clinical Trial page.

Latest updates to the Depemokimab in Severe Asthma Clinical Trial page
- Check11 days agoChange DetectedIQVIA Pty Ltd was added to the Collaborators and Investigators section and Iqvia Pty Ltd was removed, reflecting capitalization normalization of the organization name.SummaryDifference0.0%

- Check18 days agoChange DetectedPublications section updated with a new reference: Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1/-2 Studies.SummaryDifference0.0%

- Check26 days agoChange DetectedA new publication citation has been added: Heffler E et al., Depemokimab demonstrates efficacy in patients with type 2 asthma with comorbid CRSwNP: Phase III SWIFT-1/-2 analysis. Front Allergy, 2026.SummaryDifference0.0%

- Check33 days agoChange DetectedRevision: v3.5.0 has been added to the page. The previous revision entry, v3.4.3, has been removed.SummaryDifference0.0%

- Check47 days agoChange DetectedAdded a new publication entry for Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2 (Adv Ther, 2026; doi: 10.1007/s12325-025-03457-4) and removed the 2025 ahead-of-print reference. The study record version has been updated to v3.4.3.SummaryDifference0.1%

- Check69 days agoChange DetectedRevision: v3.4.2 has been added in place of v3.4.1.SummaryDifference0.0%

Stay in the know with updates to Depemokimab in Severe Asthma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Depemokimab in Severe Asthma Clinical Trial page.